“NDELA” Nitrosamine in pharma products

Pharmaceutical companies, involved in the production of finished pharmaceutical products, such as topical creams or foams, following the risk assessment envisaged by EMA guidelines, must investigate the presence of any traces of N-Nitrosodiethanolamine (NDELA) in their finished products.

Learn more

Latest update: 21/09/2021 11:29:18

In the same section

This site uses cookies, including from third parties, to improve the browsing experience. If you want to know more you can consult our Cookie Policy . You can freely lend, refuse or withdraw your consent at any time by accessing the preferences panel. You can consent to the use of these technologies by consenting to this information.